Category Archives: Psoriasis

Prayer Against Growths; Tumors, Cysts, Polyps, Warts, Moles, Fungus, Psoriasis
Specific prayer against growths in the body, whatever they may be; tumors, cysts, polyps, warts, moles, tags, fungus, psoriasis and the like. https://www.fac...

By: UnforgettableLife

Read this article:
Prayer Against Growths; Tumors, Cysts, Polyps, Warts, Moles, Fungus, Psoriasis - Video

How To Treat Psoriasis Of The Scalp, Plaque Psoriasis Natural Treatment, Treatment For Psoriasis On
How To Treat Psoriasis Of The Scalp, Plaque Psoriasis Natural Treatment, Treatment For Psoriasis On Face http://psoriasis-cure-video.info-pro.co Medical rese...

By: Home Fixes

Original post:
How To Treat Psoriasis Of The Scalp, Plaque Psoriasis Natural Treatment, Treatment For Psoriasis On - Video

Guttate Psoriasis, Scalp Psoriasis, Home Remedies For Psoriasis, How To Treat Scalp Psoriasis
Guttate Psoriasis, Scalp Psoriasis, Home Remedies For Psoriasis, How To Treat Scalp Psoriasis http://psoriasis-cure-video.info-pro.co Medical researcher, nut...

By: Guttate Psoriasis

Read more:
Guttate Psoriasis, Scalp Psoriasis, Home Remedies For Psoriasis, How To Treat Scalp Psoriasis - Video

New Treatments For Psoriasis, Home Treatment For Psoriasis, Psoriasis Causes And Treatment
New Treatments For Psoriasis, Home Treatment For Psoriasis, Psoriasis Causes And Treatment http://psoriasis-cure-video.info-pro.co Are You Suffering From Any...

By: Home Fixes

Original post:
New Treatments For Psoriasis, Home Treatment For Psoriasis, Psoriasis Causes And Treatment - Video

Psoriasis Scrape - Tracks in the snow
It #39;s been a while youtube! But due to popular demand, here you go!

By: Huy Ngo

See the rest here:
Psoriasis Scrape - Tracks in the snow - Video

Tampa Dermatologist Dr. Seth Forman is expressing boundless optimism as the clinical trial for nail psoriasis his office in conducting is producing astounding results

Reformulated to specifically treat nail psoriasis, the medication Humira is being used in phase III of a clinical trial. Humira is an already available medication known to relieve pain and to reduce inflammation in a number of autoimmune diseases, including psoriasis.

Throughout the trials, the reformulated version of the medication has been given to patients in order to monitor and confirm its effectiveness. So far, the Tampa dermatologist says hes impressed with the findings.

We are happy with what weve seen so far, said Dr. Forman. This is by far the most effective nail psoriasis treatment Ive ever seen. The results are that spectacular.

The condition is a common feature seen in conjunction with cutaneous psoriasis and psoriatic arthritis. Nail psoriasis can affect as much as 50 percent of all psoriasis patients, causing distress from pain and an unsightly look, according to the Psoriasis Institute.

While the ongoing nail psoriasis clinical trials continue to move along fluidly, Dr. Forman says they are far from being over.

The trials are still in the beginning phases and there is still a lot of work to be done, said the Tampa dermatologist. We aim to continue treating patients, both new and current, until we are fully satisfied with the outcome.

Dr. Formans office offers multiple clinical trials for eczema, plaque psoriasis nail psoriasis and others. Clinical trials offer patients, insured or not, the opportunity for complimentary healthcare.

If interested in being a part of the clinical trial for nail psoriasis, or for more on Dr. Seth Forman, Tampa dermatology or Forman Dermatology and Skin Cancer Institute, please visitwww.FormanDerm.com.

About Dr. Seth Forman:Dr. Forman is a board-certified dermatologist practicing in Tampa, Florida. He was voted the Best Dermatologist in Carrollwood in 2011 and 2012 by the Carrollwood News and Tribune. In December 2011, he opened his newTampa dermatologyoffice, Forman Dermatology and Skin Cancer Institute, where he gives psoriasis sufferers access to the latest treatment options, including topical and oral medications, as well as biological and phototherapy. Dr. Forman is one of the few Tampa dermatologists to offer narrowband light therapy, which uses pharmaceutical grade light to suppress psoriasis. Hes also one of the few board-certified dermatologists in the U.S. to use the SRT-100 radiotherapy to treat basal cell carcinoma, the most common form of skin cancer.

Continue reading here:
Tampa dermatologists clinical trial for nail psoriasis generating encouraging results

Marketing Authorization Decision Expected from the European Commission in the Second Quarter

NORTH CHICAGO, Illinois, Feb. 27, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA (adalimumab) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age. If granted marketing authorization by the European Commission, HUMIRA may become the first treatment availablefor severe chronic plaque psoriasisin children and adolescents fromfour years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

"The positive response from the CHMP marks an important step in addressing the needs of children and adolescents living with severe plaque psoriasis in Europe," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Building on more than 16 years of clinical experience with HUMIRA, we look forward to the opportunity to make a positive impact on the lives of pediatric plaque psoriasis patients."

The positive opinion is based on the results of a Phase 3 study, which will be presented at an upcoming medical meeting. The review of the marketing authorization application (MAA) is being conducted under the centralized licensing procedure. If approved, the authorization will be valid in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.

Since first gaining approval 12 years ago, HUMIRA has been approved in more than 87 countries. It is currently being used to treat more than 843,000 patients worldwide1 across 10 globally approved indications.2

About Pediatric Chronic Plaque Psoriasis According to estimates from the World Health Organization, pediatric psoriasis occurs in 0.70 percent of the pediatric population,3 with no significant difference by gender.4 The chronic autoimmune disease is characterized by the rapid and excessive accumulation of skin cells, which form thick patches of inflamed, scaly skin.5 Pediatric psoriasis has similar characteristics to adult psoriasis, but in children, the psoriatic lesions are typically smaller, thinner, and less scaly.4 Beyond the physical challenges of managing the chronic skin disorder, it is also considered to have significant emotional and psychological effects.6

HUMIRA EU Therapeutic Indications2 HUMIRA is approved for use in moderate to severe rheumatoid arthritis, active juvenile idiopathic arthritis in patients who have had inadequate response to prior therapy, ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive psoriatic arthritis, moderate to severely active Crohn's Disease and moderate to severely active ulcerative colitis.See SmPC for full indication.

Important EU Safety Information2 HUMIRA is contraindicated in patients with active tuberculosis or other severe infections and in patients with moderate to severe heart failure. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with a TNF-antagonist. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache, abdominal pain, nausea, rash and musculoskeletal pain.

(see SmPC for full details at https://www.medicines.org.uk/emc/medicine/21201)

About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Continue reading here:
AbbVie's HUMIRA (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic ...

Psoriasis Diet Diary Week Twenty
Week Twenty... Good week for skin despite having some added stress in life this week. Clearance areas have grown again, forearms looking better. I #39;ll be inte...

By: Jon Maddison

More here:
Psoriasis Diet Diary Week Twenty - Video

Easy Psoriasis Cures For Instant Psoriasis Relief
DERMATOLOGIST RECOMMENDED Revitol Eczema Cream Click http://goo.gl/y5HwqF ** - Get instant Psoriasis relief by using these easy Psoriasis cures.

By: Carly Benson

Follow this link:
Easy Psoriasis Cures For Instant Psoriasis Relief - Video

This news release is available in German.

A three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4, an abbreviation for the endogenous signaling molecule Interleukin 4. The substance's ability to inhibit inflammation is well known, but its mechanism of action was not fully understood. Scientists from the Technische Universitt Mnchen (TUM) and the University of Tbingen have now shown in an animal model and in a study on patients exactly how IL-4 helps against psoriasis at the molecular level and the important role it plays in our immune system.

Inflammation is a defense strategy of the body against invaders. Increased amounts of blood and fluid flow into the infected areas, and the release of signaling molecules summon immune cells to the site of infection to effectively neutralize the pathogens. However, poorly coordinated or misdirected immune reactions can trigger inflammation even in the absence of external agents, thus causing undue tissue damage. This is the case in psoriasis and other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.

The body's own signaling molecule as a therapy candidate

"Together with colleagues from Tbingen, we were able to show in earlier studies that the signaling molecule IL-4 is a promising candidate for the treatment of psoriasis," explains Prof. Tilo Biedermann, who holds the chair for Dermatology and Allergology and is Director of the Clinic and Polyclinic for Dermatology and Allergology. "However, before IL-4 can be used as a standardized medication, we have to understand the exact mechanism of action - and we've now succeeded in doing just that."

The scientists followed a translational approach in their study - the laboratory findings were applied to patients without delay. They first used human and mouse cells to unravel the molecular effects of IL-4 on inflammation. To this effect, the scientists discovered that IL-4 inhibits specific immune cells in a natural way: it prevents the cells from synthesizing and releasing two signaling molecules, known as IL-23 and IL-17.

"The discovery is very interesting in that IL-23 activates special T-cells in the body, thus triggering inflammation. Evidently IL-4 is able to effectively block this pathway," says Biedermann. In subsequent experiments with mice, the scientists also found that administration of IL-4 specifically inhibits inflammation of the skin via this mechanism.

IL-4 reduces psoriasis in patients

The scientists also checked the findings from the animal model in a patient study. Twenty-two patients with psoriasis received subcutaneous injections of IL-4 over a period of six weeks. Tilo Biedermann and his colleagues then examined samples from the patients' affected skin areas before and after the treatment.

The results confirmed the previous experiments: Before treatment with IL-4, the study participants had high levels of IL-23 and IL-17 in their inflamed and itchy skin. After successful treatment, the two substances were barely detectable. The result was that inflammation and psoriatic skin changes had disappeared.

Read the original:
Marshaling the body's own weapons against psoriasis